Chairman of the board Q3 conference call
direct audio file link: (20 minutes worth listening to)
Premacure and Insmed - retinopathy and more: (check commercial partners)
Link from seekingalpha on Insmed no debt and 124mln cash position:
Italian ALS data link:
USA pals comments:(due to report on nov 30th to the fda and insmed on their experience with the IND use of iplex in ALS patient (small group of USA
Message board for Insmed is very active with a lot of innuendo and implicit lies, whilst short interest is low and institutuonal ownership grows.
Merck recently bought Avecia (old relation Insmed and Avecia dating back from 2002)
Evidence letters from 2007 in strong support of IPLEX. various indications beyond scope of just MMD.
Direct court document pdfs.
Bp3 and herceptine (just one example of multiple abstracts available, also much more recent)
EU patent update january 2010(!)
Approved patent on purification will make igf1/igf1bp3 the domain of insmed.
Patent claim covers and applicable to accepted pharmaceutical salts.There is no way around this patent if one wants to achieve purity of higher than
80%. (insmed has 99%+ purity due to their processes)
Deafening silence since nov 30th as well
From ALS worldwide
"Dear Scott ,
The Iplex Saga:
Many want to know what's happening with Iplex. How are the ALS WORLDWIDE patients who have access to this medication doing, is it ever going to be
released to others and is it still being distributed in Europe? There is, at this time, no indication that the numbers of patients who currently have
access to Iplex will be expanded or continued past a total period of 24 months as was stated in Insmed's last press release. Whereas we wish we knew
more, we have very little information to release. Many patients we monitor have experienced a range of improvements including reductions in choking,
greater ease with chewing and swallowing, improved speech and respiration, and some increased limb strength. What we do know is that any gains
experienced can only be maintained while Iplex continues to be used. Greater details will be released on or after November 30, 2009, by which time a
report will have been submitted to both Insmed and the FDA."